Quick Links

Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Merck Sharp & Dohme Corp.

Not an official event of the 2018 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or the Conquer Cancer Foundation.

Privacy Policy
Terms & Conditions
Executive Board
Faculty Portal
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

ASCO: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary Cancers

ASCO: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary Cancers

Friday, June 1, 2018
Time: 7:00 PM – 9:00 PM
Dinner and registration: 6:30 PM – 7:00 PM

Hilton Chicago
Williford Room (Third Level)
720 South Michigan Avenue
Chicago, IL 60605


Unmet clinical needs remain in the management of genitourinary (GU) cancers, particularly for your patients with advanced forms of these diseases. In addition, busy clinicians like you are managing a heterogeneous patient population of GU cancers, making it a challenge to maintain the quality of care for these distinct tumors, due to the rapid pace at which the field of GU malignancies continues to evolve.

At this live CME satellite symposium, presented as an ancillary event to the 2018 ASCO Annual Meeting, you will hear a renowned panel of GU cancer experts discuss and highlight the emerging data for patients with metastatic renal cell carcinoma (mRCC), advanced bladder cancer, prostate cancer, and including less-common but important malignancies such as testicular cancer and penile cancer. Through interactive case discussions, data presentations, question-and-answer sessions, and the always popular Medical Crossfire®, you will have direct access to expert guidance on the interpretation of core concepts in an effort to forecast future application of evolving strategies for clinical practice.

This program will provide you with the opportunity to increase your confidence and competence in selecting and sequencing optimal treatment for GU cancers, particularly newer treatment options. For busy clinicians who attend major oncology conferences, such as the ASCO Annual Meeting, this is an excellent opportunity to interpret the data and to learn how to safely apply these novel approaches within the context of real-world, practical case scenarios.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Merck Sharp & Dohme Corp.

Target Audience:

This educational program is directed toward medical oncologists interested in the treatment of genitourinary cancers. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with genitourinary cancers will be invited to participate.

Learning Objectives:

Upon completion of this activity, participants should be better prepared to:

  1. Outline the use of patient- and disease-specific characteristics to inform clinical decision making in the management of patients with GU malignancies
  2. Discuss current strategies and practice-changing evidence for the management of patients with GU malignancies across multiple lines of care
  3. Explain how to proactively mitigate expected treatment-related toxicities associated with immunotherapeutic and targeted approaches to treating GU cancers
  4. Apply emerging clinical trial data for the management of GU malignancies in the context of changing treatment paradigms in the field

Program Chair

Charles G. Drake, MD, PhD
Professor of Oncology and Immunology
Director, Genitourinary Cancer Program
Co-director of the Immunotherapy Program
Herbert Irving Comprehensive Cancer Center
Columbia University Medical Center
New York, NY

Click to see all our ASCO programs!

Become a Member

Forgot Password?
Calendar of Events
Filter By